Therapeutic frontiers in Alzheimer's disease

S. W. Miller, J. M. Mahoney, Michael Wong Jann

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Alzheimer's disease (AD), the most common type of primary degenerative dementia, is the leading cause of cognitive impairment in the geriatric population. It is a devastating illness, both to the patients and the families involved. Although much research continues to be conducted, the etiology and effective treatment for the disease remain to be found. One of the primary hypotheses of the disease is that the cognitive decline of AD involves the loss of related cholinergic neurons. Although the cholinergic theory is still valid, efforts aimed at increasing levels of acetylcholine have yielded disappointing results. Currently, in the United States, several drugs are in various stages of development for the treatment of AD. The mechanisms of these agents include cerebral protectants, enhancers of neuronal signal amplification, tonic stimulation, and nerve growth factors. Other avenues being investigated include the development of novel drug delivery systems to enhance CNS concentrations of therapeutic agents.

Original languageEnglish
Pages (from-to)217-231
Number of pages15
JournalPharmacotherapy
Volume12
Issue number3
Publication statusPublished - 30 Jun 1992

    Fingerprint

Cite this

Miller, S. W., Mahoney, J. M., & Jann, M. W. (1992). Therapeutic frontiers in Alzheimer's disease. Pharmacotherapy, 12(3), 217-231.